Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-2028
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Global Scenario
The healthcare industry is a multi-billion-dollar market consisting of various verticals aimed at improving patient lives. The industry has experienced considerable advancement in terms of diagnosis and treatment, yet cancer remains as one of the leading causes of death. Cancer acts as one of the major issues of the global healthcare industry, as it is the second leading cause of death all around the world (according to WHO). The effects of cancer have had a major impact on society across the world and currently accounts for almost 70% of death in low- and middle-income countries. As per GLOBOCAN data, there were almost 14 million cancer cases globally in 2012, which claimed almost 8 million patient lives. As a result, significant scientific innovation is taking place in the field of oncology for the development of novel oncology medicines that are significantly propelling the growth of cancer treatment market.
Immunotherapy is a Type of Personalized Medicine
Cancer immunotherapy or, immuno-oncology, is the treatment that utilises the body’s own immune system to combat cancer. These immunotherapy treatments either boost the body’s immune system or may act on immune system to identify and destroy the cancerous cells. Immunotherapy is a type of personalized medicine that works better for certain types of cancer. Globally, patients are displaying a positive response towards advanced cancer therapy drugs which effectively help manage and treat their medical conditions. This, in turn, is gradually increasing the adoption rate of the cancer immunotherapy drugs.
Scope of Cancer Immunotherapy Market Report
The cancer immunotherapy market consists of products such as monoclonal antibodies, check point inhibitors, cancer vaccines and other medicinal treatments such as adoptive cell therapies and oncolytic viral therapies used in the treatment of cancer. The market analysis report includes an in-depth examination of the key ecosystem players, key strategies, and developments taking place in this market.
The purpose of the study is to gain a holistic view of the global cancer immunotherapy market in terms of various factors influencing the same, such as key market trends, competitive and regulatory aspects of the market, scientific innovations in the oncology field, etc. The scope of the report is centred upon conducting a detailed study of the solutions allied with cancer immunotherapy market, which involves drugs used in different therapeutic applications of cancer treatment.
Market Dynamics (Market Drivers, Threats, Opportunities) and Market Segmentation
Additionally, it includes market dynamics (market drivers, opportunities, and challenges) and industry analysis. The market has been classified based on different therapeutic indications, such as breast cancer, melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, gastric cancer, and others. Geographically, the market can be segmented into five distinct regions including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.
The global cancer immunotherapy market is segmented into three different parts: ‘by products’, ‘by therapeutic indication’, and ‘by region’. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The market by region has been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and recent developments, have been discussed.
The answers to the following key questions can be derived from this report:
The key players that have been contributing significantly in the cancer immunotherapy market include Aduro Biotech, Inc., Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Gilead Sciences, Inc., among others.
Global Scenario
The healthcare industry is a multi-billion-dollar market consisting of various verticals aimed at improving patient lives. The industry has experienced considerable advancement in terms of diagnosis and treatment, yet cancer remains as one of the leading causes of death. Cancer acts as one of the major issues of the global healthcare industry, as it is the second leading cause of death all around the world (according to WHO). The effects of cancer have had a major impact on society across the world and currently accounts for almost 70% of death in low- and middle-income countries. As per GLOBOCAN data, there were almost 14 million cancer cases globally in 2012, which claimed almost 8 million patient lives. As a result, significant scientific innovation is taking place in the field of oncology for the development of novel oncology medicines that are significantly propelling the growth of cancer treatment market.
Immunotherapy is a Type of Personalized Medicine
Cancer immunotherapy or, immuno-oncology, is the treatment that utilises the body’s own immune system to combat cancer. These immunotherapy treatments either boost the body’s immune system or may act on immune system to identify and destroy the cancerous cells. Immunotherapy is a type of personalized medicine that works better for certain types of cancer. Globally, patients are displaying a positive response towards advanced cancer therapy drugs which effectively help manage and treat their medical conditions. This, in turn, is gradually increasing the adoption rate of the cancer immunotherapy drugs.
Scope of Cancer Immunotherapy Market Report
The cancer immunotherapy market consists of products such as monoclonal antibodies, check point inhibitors, cancer vaccines and other medicinal treatments such as adoptive cell therapies and oncolytic viral therapies used in the treatment of cancer. The market analysis report includes an in-depth examination of the key ecosystem players, key strategies, and developments taking place in this market.
The purpose of the study is to gain a holistic view of the global cancer immunotherapy market in terms of various factors influencing the same, such as key market trends, competitive and regulatory aspects of the market, scientific innovations in the oncology field, etc. The scope of the report is centred upon conducting a detailed study of the solutions allied with cancer immunotherapy market, which involves drugs used in different therapeutic applications of cancer treatment.
Market Dynamics (Market Drivers, Threats, Opportunities) and Market Segmentation
Additionally, it includes market dynamics (market drivers, opportunities, and challenges) and industry analysis. The market has been classified based on different therapeutic indications, such as breast cancer, melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, gastric cancer, and others. Geographically, the market can be segmented into five distinct regions including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.
The global cancer immunotherapy market is segmented into three different parts: ‘by products’, ‘by therapeutic indication’, and ‘by region’. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The market by region has been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and recent developments, have been discussed.
The answers to the following key questions can be derived from this report:
- What is cancer immunotherapy? What are the products included in immunotherapy?
- What are the major market drivers, restraints, and opportunities in the global cancer immunotherapy market?
- What were the market shares of the leading segments, and sub-segments of the global cancer immunotherapy market in 2017 and what will be its share in 2028?
- How will each segment of the global cancer immunotherapy market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
- What are the influencing factors that may affect the market share of the key players?
- What are the key developmental strategies implemented by the key players to stand out in this market?
- What are the major regulatory authorities/ associations/ consortiums affecting the cancer immunotherapy market and what are the main designations facilitating development and approval of cancer drugs?
- Which product segment is expected to register the highest CAGR for the global cancer immunotherapy market?
- How has the market been segmented based on therapeutic indication? Which therapeutic indication segment had the largest share, and the fastest growth rate in the global cancer immunotherapy market?
- Which geographical region will contribute to the highest sales of the cancer immunotherapy drugs during the forecast period and which will have the highest CAGR?
- What are major companies developing cancer immunotherapy drugs targeted for different therapeutic indication?
The key players that have been contributing significantly in the cancer immunotherapy market include Aduro Biotech, Inc., Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Gilead Sciences, Inc., among others.
EXECUTIVE SUMMARY
1 MARKET OVERVIEW
1.1 Cancer Immunotherapy
1.2 Types of Cancer Immunotherapy
2 MARKET DYNAMICS
2.1 Drivers
2.1.1 Rising Prevalence of Cancer
2.1.2 Unmet Medical Needs of Cancer Patients
2.1.3 Rising R&D Expenditure in the Immuno-Oncology Segment
2.1.4 Advancement of Precision Medicine in Immuno-oncology
2.2 Restraints
2.2.1 High Cost of Treatment
2.2.2 Adverse Effects of Immunotherapy Treatment
2.3 Opportunities
2.3.1 Development of Targeted Therapy
2.3.2 Development of Healthcare Infrastructure and Reimbursement Policies in Emerging Economies
2.3.3 Combination Therapy
3 COMPETITIVE LANDSCAPE
3.1 Key Developmental Strategies
3.1.1 Product Approval
3.1.2 Agreements, Collaborations and Partnerships
3.1.3 Clinical Study
3.1.4 Regulatory Designation
3.1.5 Acquisition
3.1.6 Others
3.2 Market Share Analysis
4 INDUSTRY INSIGHTS
4.1 Regulatory Organizations/ Associations/ Consortiums
4.2 Patent Landscape
4.3 Regulatory Designations
5 GLOBAL CANCER IMMUNOTHERAPY MARKET (BY PRODUCT)
5.1 Monoclonal Antibodies
5.2 Checkpoint Inhibitors
5.2.1 CTLA-4 Inhibitors
5.2.2 PD-L1 Inhibitors/ PD-1 Inhibitors
5.3 Cancer Vaccines
5.3.1 Other Cancer Therapies
5.3.1.1 Oncolytic Viruses
5.3.1.2 Adoptive Cell Transfer
6 GLOBAL CANCER IMMUNOTHERAPY MARKET (BY THERAPEUTIC INDICATION)
6.1 Breast Cancer
6.2 Non-Small Cell Lung Cancer (NSCLC)
6.3 Melanoma
6.4 Colorectal Cancer
6.5 Renal Cell Carcinoma
6.6 Gastric Cancer
6.7 Others
7 GLOBAL CANCER IMMUNOTHERAPY MARKET (BY REGION)
7.1 North America
7.1.1 The U.S.
7.1.2 Canada
7.2 Europe
7.2.1 Germany
7.2.2 The U.K.
7.2.3 France
7.2.4 Spain
7.2.5 Italy
7.2.6 Russia
7.2.7 Poland
7.2.8 Austria
7.2.9 Switzerland
7.2.10 Belgium
7.2.11 The Netherlands
7.2.12 Sweden
7.2.13 Finland
7.2.14 Denmark
7.2.15 Ireland
7.2.16 Rest-of-Europe
7.3 Asia-Pacific
7.3.1 China
7.3.2 Japan
7.3.3 India
7.3.4 Australia
7.3.5 South Korea
7.3.6 New Zealand
7.3.7 Malaysia
7.3.8 Bangladesh
7.3.9 Rest-of-Asia-Pacific
7.4 Latin America
7.4.1 Brazil
7.4.2 Mexico
7.4.3 Argentina
7.4.4 Rest-of-Latin-America
7.5 Rest-of-the-World (RoW)
7.5.1 Saudi Arabia
7.5.2 The U.A.E.
7.5.3 South Africa
7.5.4 Israel
7.5.5 Others
8 COMPANY PROFILES
8.1 Overview
8.2 Aduro Biotech
8.2.1 Company Overview
8.2.2 Role of Aduro Biotech in Cancer Immunotherapy Market
8.2.3 Financials
8.2.4 Key Insights about the Financial Health of the Company
8.2.5 SWOT Analysis
8.3 Amgen
8.3.1 Company Overview
8.3.2 Role of Amgen Inc in the Cancer Immunotherapy Market
8.3.3 Financials
8.3.4 Key Insights about Financial Health of the Company
8.3.5 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Role of AstraZeneca in Cancer Immunotherapy Market
8.4.3 Financials
8.4.4 Key Insights about Financial Health of the Company
8.4.5 SWOT Analysis
8.5 Bristol-Myers Squibb
8.5.1 Company Overview
8.5.2 Role of Bristol-Myers Squibb in the Cancer Immunotherapy Market
8.5.3 Financials
8.5.4 Key Insights about Financial Health of the Company
8.5.5 SWOT Analysis
8.6 Celgene Corporation
8.6.1 Company Overview
8.6.2 Role of Celgene Corporation in Cancer Immunotherapy Market
8.6.3 Financials
8.6.4 Key Insights about Financial Health of the Company
8.6.5 SWOT Analysis
8.7 DNAtrix Therapeutics
8.7.1 Company Overview
8.7.2 Role of DNAtrix Therapeutics in Cancer Immunotherapy Market
8.7.3 SWOT Analysis
8.8 Eli Lilly and Company
8.8.1 Company Overview
8.8.2 Role of Eli Lilly and Company in Cancer Immunotherapy Market
8.8.3 Financials
8.8.4 Key Insights about Financial Health of the Company
8.8.5 SWOT Analysis
8.9 Gilead Sciences, Inc.
8.9.1 Company Overview
8.9.2 Role of Gilead Sciences, Inc. in Cancer Immunotherapy Market
8.9.3 Financials
8.9.4 Key Insights About the Financial Health of the Company
8.9.5 SWOT Analysis
8.10 Fate Therapeutics
8.10.1 Company Overview
8.10.2 Role of Fate Therapeutics in cancer immunotherapy market
8.10.3 Financials
8.10.4 Key Insights about the Financial Health of the Company
8.10.5 SWOT Analysis
8.11 F. Hoffmann La Roche
8.11.1 Company Overview
8.11.2 Role of F. Hoffmann La Roche in Cancer Immunotherapy market
8.11.3 Financials
8.11.4 Key Insights About the Financial Health of the Company
8.11.5 SWOT Analysis
8.12 JOHNSON & JOHNSON
8.12.1 Company Overview
8.12.2 Role of Johnson & Johnson in Cancer Immunotherapy Market
8.12.3 Financials
8.12.4 Key Insights about the Financial Health of the Company
8.12.5 SWOT Analysis
8.13 Merck & Co., Inc.
8.13.1 Company Overview
8.13.2 Role of Merck & Co, Inc. in Cancer Immunotherapy Market
8.13.3 Financials
8.13.4 Key Insights about the Financial Health of Company
8.13.5 SWOT Analysis
8.14 Novartis AG
8.14.1 Company Overview
8.14.2 Role of Novartis AG in Cancer Immunotherapy Market
8.14.3 Financials
8.14.4 Key Insights about the Financial Health of Company
8.14.5 SWOT Analysis
8.15 Pfizer, Inc.
8.15.1 Company Overview
8.15.2 Role of Pfizer, Inc. in Cancer Immunotherapy Market
8.15.3 Financials
8.15.4 Key Insights about the Financial Health of the Company
8.15.5 SWOT Analysis
8.16 Precision BioSciences, Inc.
8.16.1 Company Overview
8.16.2 Role of Precision BioSciences, Inc. in Cancer Immunotherapy Market
8.16.3 SWOT Analysis
8.17 IOVANCE BIOTHERAPEUTICS, INC.: Snapshot
8.17.1 Company Overview
8.17.2 Role of IOVANCE BIOTHERAPEUTICS, INC. in cancer immunotherapy market
9 RESEARCH SCOPE AND METHODOLOGY
9.1 Scope of the Report
9.2 Global Cancer Immunotherapy Market Segmentation
9.3 Research Methodology
9.3.1 Primary Research
9.3.2 Secondary Research
9.3.3 Key Data Points from Primary and Secondary Sources
9.3.4 Data Triangulation
9.3.5 Top-Down Approach
9.3.6 Bottom- Up Approach
9.4 Assumptions and Limitations
1 MARKET OVERVIEW
1.1 Cancer Immunotherapy
1.2 Types of Cancer Immunotherapy
2 MARKET DYNAMICS
2.1 Drivers
2.1.1 Rising Prevalence of Cancer
2.1.2 Unmet Medical Needs of Cancer Patients
2.1.3 Rising R&D Expenditure in the Immuno-Oncology Segment
2.1.4 Advancement of Precision Medicine in Immuno-oncology
2.2 Restraints
2.2.1 High Cost of Treatment
2.2.2 Adverse Effects of Immunotherapy Treatment
2.3 Opportunities
2.3.1 Development of Targeted Therapy
2.3.2 Development of Healthcare Infrastructure and Reimbursement Policies in Emerging Economies
2.3.3 Combination Therapy
3 COMPETITIVE LANDSCAPE
3.1 Key Developmental Strategies
3.1.1 Product Approval
3.1.2 Agreements, Collaborations and Partnerships
3.1.3 Clinical Study
3.1.4 Regulatory Designation
3.1.5 Acquisition
3.1.6 Others
3.2 Market Share Analysis
4 INDUSTRY INSIGHTS
4.1 Regulatory Organizations/ Associations/ Consortiums
4.2 Patent Landscape
4.3 Regulatory Designations
5 GLOBAL CANCER IMMUNOTHERAPY MARKET (BY PRODUCT)
5.1 Monoclonal Antibodies
5.2 Checkpoint Inhibitors
5.2.1 CTLA-4 Inhibitors
5.2.2 PD-L1 Inhibitors/ PD-1 Inhibitors
5.3 Cancer Vaccines
5.3.1 Other Cancer Therapies
5.3.1.1 Oncolytic Viruses
5.3.1.2 Adoptive Cell Transfer
6 GLOBAL CANCER IMMUNOTHERAPY MARKET (BY THERAPEUTIC INDICATION)
6.1 Breast Cancer
6.2 Non-Small Cell Lung Cancer (NSCLC)
6.3 Melanoma
6.4 Colorectal Cancer
6.5 Renal Cell Carcinoma
6.6 Gastric Cancer
6.7 Others
7 GLOBAL CANCER IMMUNOTHERAPY MARKET (BY REGION)
7.1 North America
7.1.1 The U.S.
7.1.2 Canada
7.2 Europe
7.2.1 Germany
7.2.2 The U.K.
7.2.3 France
7.2.4 Spain
7.2.5 Italy
7.2.6 Russia
7.2.7 Poland
7.2.8 Austria
7.2.9 Switzerland
7.2.10 Belgium
7.2.11 The Netherlands
7.2.12 Sweden
7.2.13 Finland
7.2.14 Denmark
7.2.15 Ireland
7.2.16 Rest-of-Europe
7.3 Asia-Pacific
7.3.1 China
7.3.2 Japan
7.3.3 India
7.3.4 Australia
7.3.5 South Korea
7.3.6 New Zealand
7.3.7 Malaysia
7.3.8 Bangladesh
7.3.9 Rest-of-Asia-Pacific
7.4 Latin America
7.4.1 Brazil
7.4.2 Mexico
7.4.3 Argentina
7.4.4 Rest-of-Latin-America
7.5 Rest-of-the-World (RoW)
7.5.1 Saudi Arabia
7.5.2 The U.A.E.
7.5.3 South Africa
7.5.4 Israel
7.5.5 Others
8 COMPANY PROFILES
8.1 Overview
8.2 Aduro Biotech
8.2.1 Company Overview
8.2.2 Role of Aduro Biotech in Cancer Immunotherapy Market
8.2.3 Financials
8.2.4 Key Insights about the Financial Health of the Company
8.2.5 SWOT Analysis
8.3 Amgen
8.3.1 Company Overview
8.3.2 Role of Amgen Inc in the Cancer Immunotherapy Market
8.3.3 Financials
8.3.4 Key Insights about Financial Health of the Company
8.3.5 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Role of AstraZeneca in Cancer Immunotherapy Market
8.4.3 Financials
8.4.4 Key Insights about Financial Health of the Company
8.4.5 SWOT Analysis
8.5 Bristol-Myers Squibb
8.5.1 Company Overview
8.5.2 Role of Bristol-Myers Squibb in the Cancer Immunotherapy Market
8.5.3 Financials
8.5.4 Key Insights about Financial Health of the Company
8.5.5 SWOT Analysis
8.6 Celgene Corporation
8.6.1 Company Overview
8.6.2 Role of Celgene Corporation in Cancer Immunotherapy Market
8.6.3 Financials
8.6.4 Key Insights about Financial Health of the Company
8.6.5 SWOT Analysis
8.7 DNAtrix Therapeutics
8.7.1 Company Overview
8.7.2 Role of DNAtrix Therapeutics in Cancer Immunotherapy Market
8.7.3 SWOT Analysis
8.8 Eli Lilly and Company
8.8.1 Company Overview
8.8.2 Role of Eli Lilly and Company in Cancer Immunotherapy Market
8.8.3 Financials
8.8.4 Key Insights about Financial Health of the Company
8.8.5 SWOT Analysis
8.9 Gilead Sciences, Inc.
8.9.1 Company Overview
8.9.2 Role of Gilead Sciences, Inc. in Cancer Immunotherapy Market
8.9.3 Financials
8.9.4 Key Insights About the Financial Health of the Company
8.9.5 SWOT Analysis
8.10 Fate Therapeutics
8.10.1 Company Overview
8.10.2 Role of Fate Therapeutics in cancer immunotherapy market
8.10.3 Financials
8.10.4 Key Insights about the Financial Health of the Company
8.10.5 SWOT Analysis
8.11 F. Hoffmann La Roche
8.11.1 Company Overview
8.11.2 Role of F. Hoffmann La Roche in Cancer Immunotherapy market
8.11.3 Financials
8.11.4 Key Insights About the Financial Health of the Company
8.11.5 SWOT Analysis
8.12 JOHNSON & JOHNSON
8.12.1 Company Overview
8.12.2 Role of Johnson & Johnson in Cancer Immunotherapy Market
8.12.3 Financials
8.12.4 Key Insights about the Financial Health of the Company
8.12.5 SWOT Analysis
8.13 Merck & Co., Inc.
8.13.1 Company Overview
8.13.2 Role of Merck & Co, Inc. in Cancer Immunotherapy Market
8.13.3 Financials
8.13.4 Key Insights about the Financial Health of Company
8.13.5 SWOT Analysis
8.14 Novartis AG
8.14.1 Company Overview
8.14.2 Role of Novartis AG in Cancer Immunotherapy Market
8.14.3 Financials
8.14.4 Key Insights about the Financial Health of Company
8.14.5 SWOT Analysis
8.15 Pfizer, Inc.
8.15.1 Company Overview
8.15.2 Role of Pfizer, Inc. in Cancer Immunotherapy Market
8.15.3 Financials
8.15.4 Key Insights about the Financial Health of the Company
8.15.5 SWOT Analysis
8.16 Precision BioSciences, Inc.
8.16.1 Company Overview
8.16.2 Role of Precision BioSciences, Inc. in Cancer Immunotherapy Market
8.16.3 SWOT Analysis
8.17 IOVANCE BIOTHERAPEUTICS, INC.: Snapshot
8.17.1 Company Overview
8.17.2 Role of IOVANCE BIOTHERAPEUTICS, INC. in cancer immunotherapy market
9 RESEARCH SCOPE AND METHODOLOGY
9.1 Scope of the Report
9.2 Global Cancer Immunotherapy Market Segmentation
9.3 Research Methodology
9.3.1 Primary Research
9.3.2 Secondary Research
9.3.3 Key Data Points from Primary and Secondary Sources
9.3.4 Data Triangulation
9.3.5 Top-Down Approach
9.3.6 Bottom- Up Approach
9.4 Assumptions and Limitations
LIST OF TABLES
Table 1: Total Regional Geriatric Population (%), 2015 and 2030
Table 2: Impact analysis of Market Drivers
Table 3: Impact Analysis of Market Restraints
Table 1.1: Estimated New Cases and Estimated Deaths in 2018 as per American Cancer Society
Table 2.1: R&D Expense of Major Companies
Table 3.1: Key Company Acquisitions, 2015-2018
Table 4.1: Regulatory Organizations/ Associations.
Table 4.2: Important Regulatory Designations
Table 5.1: List of Monoclonal Antibodies Used in Immunotherapy
Table 5.2: PD-L1 Inhibitors and Their FDA Approved Indication
Table 5.3: PD-1 Inhibitors and Their FDA Approved Indication
Table 6.1: Estimated Incidence, Mortality and Prevalence of Breast Cancer in 2012 (Numbers in thousands)
Table 6.2: Top 25 countries with the highest rates of breast cancer in 2018:
Table 6.3: Estimated Incidence, Mortality, and Prevalence of Lung Cancer (for both sexes) in 2012 (Numbers in thousands)
Table 6.4: NSCLC: 5-Year Survival Rate by Stage
Table 6.5: Age Standardized rate of Colorectal cancer in 2018
Table 6.6: Estimated Incidence, Mortality, and Prevalence of Different Cancer (for both sexes) Worldwide in 2012
Table 6.7: Cervical Cancer Rates: Top 20 Countries in 2018
Table 6.8: Leukaemia: Top 10 Countries with Incidence Rates
Table 7.1: The U.S. Estimated Age-Standardized Incidence Rates in 2018
Table 7.2: Canada Estimated Age-Standardized Incidence Rates in 2018
Table 7.3: Germany Estimated Age-Standardized Incidence Rates in 2018
Table 7.4: The U.K. Estimated Age-Standardized Incidence Rates in 2018
Table 7.5: China Estimated Age-Standardized Incidence Rates in 2018
Table 7.6: Japan Estimated Age-Standardized Incidence Rates in 2018
Table 7.7: India Estimated Age-Standardized Incidence Rates in 2018
Table 7.8: Australia Estimated Age-Standardized Incidence Rates in 2018
Table 7.9: Brazil Estimated Age-Standardized Incidence Rates in 2018
Table 7.10: Mexico Estimated Age-Standardized Incidence Rates in 2018
Table 7.11: Argentina Estimated Age-Standardized Incidence Rates in 2018
Table 8.1: Aduro Biotech: Pipeline Products
Table 8.2: Celgene Product Pipeline
Table 8.3: DNAtrix Therapeutics: Pipeline Products
Table 8.4: Fate Therapeutics: Pipeline Products
Table 1: Total Regional Geriatric Population (%), 2015 and 2030
Table 2: Impact analysis of Market Drivers
Table 3: Impact Analysis of Market Restraints
Table 1.1: Estimated New Cases and Estimated Deaths in 2018 as per American Cancer Society
Table 2.1: R&D Expense of Major Companies
Table 3.1: Key Company Acquisitions, 2015-2018
Table 4.1: Regulatory Organizations/ Associations.
Table 4.2: Important Regulatory Designations
Table 5.1: List of Monoclonal Antibodies Used in Immunotherapy
Table 5.2: PD-L1 Inhibitors and Their FDA Approved Indication
Table 5.3: PD-1 Inhibitors and Their FDA Approved Indication
Table 6.1: Estimated Incidence, Mortality and Prevalence of Breast Cancer in 2012 (Numbers in thousands)
Table 6.2: Top 25 countries with the highest rates of breast cancer in 2018:
Table 6.3: Estimated Incidence, Mortality, and Prevalence of Lung Cancer (for both sexes) in 2012 (Numbers in thousands)
Table 6.4: NSCLC: 5-Year Survival Rate by Stage
Table 6.5: Age Standardized rate of Colorectal cancer in 2018
Table 6.6: Estimated Incidence, Mortality, and Prevalence of Different Cancer (for both sexes) Worldwide in 2012
Table 6.7: Cervical Cancer Rates: Top 20 Countries in 2018
Table 6.8: Leukaemia: Top 10 Countries with Incidence Rates
Table 7.1: The U.S. Estimated Age-Standardized Incidence Rates in 2018
Table 7.2: Canada Estimated Age-Standardized Incidence Rates in 2018
Table 7.3: Germany Estimated Age-Standardized Incidence Rates in 2018
Table 7.4: The U.K. Estimated Age-Standardized Incidence Rates in 2018
Table 7.5: China Estimated Age-Standardized Incidence Rates in 2018
Table 7.6: Japan Estimated Age-Standardized Incidence Rates in 2018
Table 7.7: India Estimated Age-Standardized Incidence Rates in 2018
Table 7.8: Australia Estimated Age-Standardized Incidence Rates in 2018
Table 7.9: Brazil Estimated Age-Standardized Incidence Rates in 2018
Table 7.10: Mexico Estimated Age-Standardized Incidence Rates in 2018
Table 7.11: Argentina Estimated Age-Standardized Incidence Rates in 2018
Table 8.1: Aduro Biotech: Pipeline Products
Table 8.2: Celgene Product Pipeline
Table 8.3: DNAtrix Therapeutics: Pipeline Products
Table 8.4: Fate Therapeutics: Pipeline Products
LIST OF FIGURES
Figure 1: Global Cancer Immunotherapy Market, 2017 and 2028
Figure 2: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
Figure 3: Global Cancer Immunotherapy Market (by Product), 2017 and 2028
Figure 4: Global Cancer Immunotherapy Market (by Therapeutic Indication), 2017 and 2028
Figure 5: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
Figure 1.1: Treatment for Cancer
Figure 1.2: Global Cancer Immunotherapy Market, 2017-2028 ($Billion)
Figure 1.3: Key Players Involved in Cancer Immunotherapy
Figure 2.1: Market Dynamics
Figure 3.1: Share of Key Developmental Strategies, 2015-2018
Figure 3.2: Product Approvals, (by Company), 2015-2018
Figure 3.3: Agreements, Collaborations and Partnerships, (by Company), 2015-2018
Figure 3.4: Clinical Study, (by Company), 2015-2018
Figure 3.5: Regulatory Designations, (by Company), 2015-2018
Figure 3.6: Other Strategies (by Company), 2015-2018
Figure 3.7: Market Share Analysis, 2017 and 2018
Figure 4.1: Share of Patents by Ownership, 2015-2018
Figure 5.1: Global Monoclonal Antibodies Market, 2017-2028
Figure 5.2: Global Checkpoint Inhibitors Market, 2017-2028
Figure 5.3: Global Cancer Vaccine Market, 2017-2028
Figure 5.4: Development of CAR-T Therapy
Figure 5.5: Global Cancer Immunotherapy Market for Other Products, 2017-2028
Figure 6.1: Types of Therapeutic Cancer Indications
Figure 6.2: Global Breast Cancer Immunotherapy Market, 2017-2028
Figure 6.3: Global NSCLC Immunotherapy Market, 2017-2028
Figure 6.4: Global Melanoma Immunotherapy Market, 2017-2028
Figure 6.5: Global Colorectal Cancer Immunotherapy Market, 2017-2028
Figure 6.6: Global Renal Cell Carcinoma Immunotherapy Market, 2017-2028
Figure 6.7: Global Gastric Cancer Immunotherapy Market, 2017-2028
Figure 6.8: Global Cancer Immunotherapy Market for Other Cancer Indications, 2017-2028
Figure 7.1: Global Cancer Immunotherapy (by Region)
Figure 7.2: Global Cancer Immunotherapy Market (by Region), 2017-2028
Figure 7.3: North America Cancer Immunotherapy Market
Figure 7.4: North America Cancer Immunotherapy Market, by Country
Figure 7.5: The U.S. Cancer Immunotherapy Market, 2017-2028
Figure 7.6: Canada Cancer Immunotherapy Market
Figure 7.7: Europe Cancer Immunotherapy Market
Figure 7.8: Germany Cancer Immunotherapy Market, 2017-2028
Figure 7.9: The U.K. Cancer Immunotherapy Market, 2017-2028
Figure 7.10: France Cancer Immunotherapy Market, 2017-2028
Figure 7.11: Spain Cancer Immunotherapy Market, 2017-2028
Figure 7.12: Italy Cancer Immunotherapy Market, 2018-2028
Figure 7.13: Russia Cancer Immunotherapy Market, 2018-2028
Figure 7.14: Poland Cancer Immunotherapy Market, 2018-2028
Figure 7.15: Austria Cancer Immunotherapy Market, 2018-2028
Figure 7.16: Switzerland Cancer Immunotherapy Market, 2018-2028
Figure 7.17: Belgium Cancer Immunotherapy Market, 2018-2028
Figure 7.18: The Netherlands Cancer Immunotherapy Market, 2018-2028
Figure 7.19: Sweden Cancer Immunotherapy Market, 2018-2028
Figure 7.20: Finland Cancer Immunotherapy Market, 2018-2028
Figure 7.21: Denmark Cancer Immunotherapy Market, 2018-2028
Figure 7.22: Ireland Cancer Immunotherapy Market, 2018-2028
Figure 7.23: Rest-of-Europe Cancer Immunotherapy Market, 2018-2028
Figure 7.24: Asia-Pacific Cancer Immunotherapy Market, 2017-2028
Figure 7.25: China Cancer Immunotherapy Market, 2017-2028
Figure 7.26: Japan Cancer Immunotherapy Market, 2017-2028
Figure 7.27: India Cancer Immunotherapy Market, 2017-2028
Figure 7.28: Australia Cancer Immunotherapy Market, 2017-2028
Figure 7.29: S. Korea Cancer Immunotherapy Market, 2017-2028
Figure 7.30: New Zealand Cancer Immunotherapy Market, 2017-2028
Figure 7.31: Malaysia Cancer Immunotherapy Market, 2017-2028
Figure 7.32: Bangladesh Cancer Immunotherapy Market, 2017-2028
Figure 7.33: Rest-of-Asia-Pacific Cancer Immunotherapy Market, 2017-2028
Figure 7.34: Latin America Cancer Immunotherapy Market, 2017-2028
Figure 7.35: Latin America Cancer Immunotherapy Market (by Country), 2017-2028
Figure 7.36: Brazil Cancer Immunotherapy Market, 2017-2028
Figure 7.37: Mexico Cancer Immunotherapy Market, 2017-2028
Figure 7.38: Argentina Cancer Immunotherapy Market, 2017-2028
Figure 7.39: Rest-of-Latin-America Cancer Immunotherapy Market, 2017-2028
Figure 7.40: Saudi Arabia Cancer Immunotherapy Market, 2017-2028
Figure 7.41: The U.A.E. Cancer Immunotherapy Market, 2017-2028
Figure 7.42: South Africa Cancer Immunotherapy Market, 2017-2028
Figure 7.43: Israel Cancer Immunotherapy Market, 2017-2028
Figure 7.44: Others Cancer Immunotherapy Market, 2017-2028
Figure 8.1: Aduro Biotech: Overall Financials, 2015-2017
Figure 8.2: Aduro Biotech: Research and Development Expense, 2015-2017
Figure 8.3: Aduro Biotech: SWOT Analysis
Figure 8.4: Amgen Inc: Cancer Immunotherapy Product Portfolio
Figure 8.5: Amgen Inc.: Overall Financials
Figure 8.6: Amgen Inc.: Net Revenue (by Region), 2015-2017
Figure 8.7: Amgen Inc.: R&D Expenditure, 2015-2017
Figure 8.8: Amgen Inc.: SWOT Analysis
Figure 8.9: AstraZeneca PLC: Cancer Immunotherapy Product Portfolio
Figure 8.10: AstraZeneca PLC: Overall Financials, 2015-2017
Figure 8.11: AstraZeneca PLC: Net Revenue (by Business Segment), 2015-2017
Figure 8.12: AstraZeneca PLC: Revenue: Net Revenue (by Regions), 2015-2017
Figure 8.13: AstraZeneca PLC: R&D Expenditure, 2015-2017
Figure 8.14: AstraZeneca PLC: SWOT Analysis
Figure 8.15: Bristol-Myers Squibb: Product Portfolio
Figure 8.16: Bristol-Myers Squibb: Overall Financials
Figure 8.17: Bristol-Myers Squibb: Net Revenue (by Regions), 2015-2017
Figure 8.18: Bristol-Myers Squibb: R&D Expenditure, 2015-2017
Figure 8.19: Bristol-Myers Squibb: SWOT Analysis
Figure 8.20: Celgene Corporation: Overall Financials
Figure 8.21: Celgene Corporation: Net Revenue (by Region), 2015-2017
Figure 8.22: Celgene Corporation: R&D Expenditure, 2015-2017
Figure 8.23: Celgene Corporation: SWOT Analysis
Figure 8.24: DNAtrix Therapeutics: SWOT Analysis
Figure 8.25: Eli Lilly and Company: Product Portfolio
Figure 8.26: Eli Lilly and Company: Overall Financials, 2015-2017
Figure 8.27: Eli Lilly and Company: Net Revenue (by Business Segments), 2015-2017
Figure 8.28: Eli Lilly and Company: Net Revenue (by Regions), 2015-2017
Figure 8.29: Eli Lilly and Company: Research and Development Expenditure, 2015-2017
Figure 8.30: Eli Lilly and Company: SWOT Analysis
Figure 8.31: Gilead Sciences, Inc.: Overall Financials
Figure 8.32: Gilead Sciences, Inc.: Net Revenue (by Region), 2015-2017
Figure 8.33: Gilead Sciences, Inc.: Research and Development Expenditure, 2015-2017
Figure 8.34: Gilead Sciences, Inc.: SWOT Analysis
Figure 8.35: Fate Therapeutics: Overall Financials
Figure 8.36: Fate Therapeutics: Research and Development Expenditure, 2015-2017
Figure 8.37: Fate Therapeutics: SWOT Analysis
Figure 8.38: F. Hoffmann La Roche AG: Product Portfolio
Figure 8.39: F. Hoffmann La Roche: Overall Financials
Figure 8.40: F. Hoffmann La Roche: Net Revenue (by Business Segment), 2015-2017
Figure 8.41: F. Hoffmann La Roche: Net Revenue (by Geographic Regions), 2015-2017
Figure 8.42: F. Hoffmann La Roche: Research and Development Expense, 2015-2017
Figure 8.43: F. Hoffmann La Roche: SWOT Analysis
Figure 8.44: JOHNSON & JOHNSON: Overall Financials, 2015-2017
Figure 8.45: JOHNSON & JOHNSON (by Business Segment), 2015-2017
Figure 8.46: JOHNSON & JOHNSON (by Region), 2015-2017
Figure 8.47: JOHNSON & JOHNSON: Research and Development Expense, 2015-2017
Figure 8.48 JOHNSON & JOHNSON: SWOT ANALYSIS
Figure 8.49: Merck & Co, Inc.: Product Portfolio
Figure 8.50: Merck & Co, Inc.: Overall Financials
Figure 8.51: Merck & Co, Inc. (by Business Segment), 2015-2017
Figure 8.52: Merck & Co, Inc (by Geographic Regions), 2015-2017
Figure 8.53: Merck & Co, Inc.: Research and Development Expense, 2015-2017
Figure 8.54: Merck & Co, Inc.: SWOT Analysis
Figure 8.55: Novartis AG: Cancer Immunotherapy Product Portfolio
Figure 8.56: Novartis AG: Overall Financials (2015-2017)
Figure 8.57: Novartis AG (by Business Segment), 2015-2017
Figure 8.58 Novartis AG (by Geographic Region), 2015-2017
Figure 8.59 Novartis AG: Research and Development Expenditure, 2015-2017
Figure 8.60: Novartis AG: SWOT Analysis
Figure 8.61: Pfizer, Inc.: Cancer Immunotherapy Product Portfolio
Figure 8.62: Pfizer, Inc.: Overall Financials, 2015-2017
Figure 8.63: Pfizer, Inc.: Net Revenue (by Business Segment), 2015-2017
Figure 8.64: Pfizer, Inc.: Net Revenue (by Region), 2015-2017
Figure 8.65: Pfizer, Inc.: Research and Development Expense, 2015-2017
Figure 8.66: Pfizer, Inc.: SWOT Analysis
Figure 8.67: Precision BioSciences, Inc.: SWOT Analysis
Figure 9.1: Global Cancer Immunotherapy Market Segmentation
Figure 9.2: Research Methodology
Figure 9.3: Primary Research Sources
Figure 9.4: Secondary Research Sources
Figure 9.5: Key Data Points from Primary and Secondary Sources
Figure 9.6: Data Triangulation
Figure 9.7: Top-Down Approach: Global Cancer Immunotherapy Market
Figure 9.8: Bottom-up Approach: Global Cancer Immunotherapy Market
Figure 9.9: Assumptions and Limitations
Figure 1: Global Cancer Immunotherapy Market, 2017 and 2028
Figure 2: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
Figure 3: Global Cancer Immunotherapy Market (by Product), 2017 and 2028
Figure 4: Global Cancer Immunotherapy Market (by Therapeutic Indication), 2017 and 2028
Figure 5: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
Figure 1.1: Treatment for Cancer
Figure 1.2: Global Cancer Immunotherapy Market, 2017-2028 ($Billion)
Figure 1.3: Key Players Involved in Cancer Immunotherapy
Figure 2.1: Market Dynamics
Figure 3.1: Share of Key Developmental Strategies, 2015-2018
Figure 3.2: Product Approvals, (by Company), 2015-2018
Figure 3.3: Agreements, Collaborations and Partnerships, (by Company), 2015-2018
Figure 3.4: Clinical Study, (by Company), 2015-2018
Figure 3.5: Regulatory Designations, (by Company), 2015-2018
Figure 3.6: Other Strategies (by Company), 2015-2018
Figure 3.7: Market Share Analysis, 2017 and 2018
Figure 4.1: Share of Patents by Ownership, 2015-2018
Figure 5.1: Global Monoclonal Antibodies Market, 2017-2028
Figure 5.2: Global Checkpoint Inhibitors Market, 2017-2028
Figure 5.3: Global Cancer Vaccine Market, 2017-2028
Figure 5.4: Development of CAR-T Therapy
Figure 5.5: Global Cancer Immunotherapy Market for Other Products, 2017-2028
Figure 6.1: Types of Therapeutic Cancer Indications
Figure 6.2: Global Breast Cancer Immunotherapy Market, 2017-2028
Figure 6.3: Global NSCLC Immunotherapy Market, 2017-2028
Figure 6.4: Global Melanoma Immunotherapy Market, 2017-2028
Figure 6.5: Global Colorectal Cancer Immunotherapy Market, 2017-2028
Figure 6.6: Global Renal Cell Carcinoma Immunotherapy Market, 2017-2028
Figure 6.7: Global Gastric Cancer Immunotherapy Market, 2017-2028
Figure 6.8: Global Cancer Immunotherapy Market for Other Cancer Indications, 2017-2028
Figure 7.1: Global Cancer Immunotherapy (by Region)
Figure 7.2: Global Cancer Immunotherapy Market (by Region), 2017-2028
Figure 7.3: North America Cancer Immunotherapy Market
Figure 7.4: North America Cancer Immunotherapy Market, by Country
Figure 7.5: The U.S. Cancer Immunotherapy Market, 2017-2028
Figure 7.6: Canada Cancer Immunotherapy Market
Figure 7.7: Europe Cancer Immunotherapy Market
Figure 7.8: Germany Cancer Immunotherapy Market, 2017-2028
Figure 7.9: The U.K. Cancer Immunotherapy Market, 2017-2028
Figure 7.10: France Cancer Immunotherapy Market, 2017-2028
Figure 7.11: Spain Cancer Immunotherapy Market, 2017-2028
Figure 7.12: Italy Cancer Immunotherapy Market, 2018-2028
Figure 7.13: Russia Cancer Immunotherapy Market, 2018-2028
Figure 7.14: Poland Cancer Immunotherapy Market, 2018-2028
Figure 7.15: Austria Cancer Immunotherapy Market, 2018-2028
Figure 7.16: Switzerland Cancer Immunotherapy Market, 2018-2028
Figure 7.17: Belgium Cancer Immunotherapy Market, 2018-2028
Figure 7.18: The Netherlands Cancer Immunotherapy Market, 2018-2028
Figure 7.19: Sweden Cancer Immunotherapy Market, 2018-2028
Figure 7.20: Finland Cancer Immunotherapy Market, 2018-2028
Figure 7.21: Denmark Cancer Immunotherapy Market, 2018-2028
Figure 7.22: Ireland Cancer Immunotherapy Market, 2018-2028
Figure 7.23: Rest-of-Europe Cancer Immunotherapy Market, 2018-2028
Figure 7.24: Asia-Pacific Cancer Immunotherapy Market, 2017-2028
Figure 7.25: China Cancer Immunotherapy Market, 2017-2028
Figure 7.26: Japan Cancer Immunotherapy Market, 2017-2028
Figure 7.27: India Cancer Immunotherapy Market, 2017-2028
Figure 7.28: Australia Cancer Immunotherapy Market, 2017-2028
Figure 7.29: S. Korea Cancer Immunotherapy Market, 2017-2028
Figure 7.30: New Zealand Cancer Immunotherapy Market, 2017-2028
Figure 7.31: Malaysia Cancer Immunotherapy Market, 2017-2028
Figure 7.32: Bangladesh Cancer Immunotherapy Market, 2017-2028
Figure 7.33: Rest-of-Asia-Pacific Cancer Immunotherapy Market, 2017-2028
Figure 7.34: Latin America Cancer Immunotherapy Market, 2017-2028
Figure 7.35: Latin America Cancer Immunotherapy Market (by Country), 2017-2028
Figure 7.36: Brazil Cancer Immunotherapy Market, 2017-2028
Figure 7.37: Mexico Cancer Immunotherapy Market, 2017-2028
Figure 7.38: Argentina Cancer Immunotherapy Market, 2017-2028
Figure 7.39: Rest-of-Latin-America Cancer Immunotherapy Market, 2017-2028
Figure 7.40: Saudi Arabia Cancer Immunotherapy Market, 2017-2028
Figure 7.41: The U.A.E. Cancer Immunotherapy Market, 2017-2028
Figure 7.42: South Africa Cancer Immunotherapy Market, 2017-2028
Figure 7.43: Israel Cancer Immunotherapy Market, 2017-2028
Figure 7.44: Others Cancer Immunotherapy Market, 2017-2028
Figure 8.1: Aduro Biotech: Overall Financials, 2015-2017
Figure 8.2: Aduro Biotech: Research and Development Expense, 2015-2017
Figure 8.3: Aduro Biotech: SWOT Analysis
Figure 8.4: Amgen Inc: Cancer Immunotherapy Product Portfolio
Figure 8.5: Amgen Inc.: Overall Financials
Figure 8.6: Amgen Inc.: Net Revenue (by Region), 2015-2017
Figure 8.7: Amgen Inc.: R&D Expenditure, 2015-2017
Figure 8.8: Amgen Inc.: SWOT Analysis
Figure 8.9: AstraZeneca PLC: Cancer Immunotherapy Product Portfolio
Figure 8.10: AstraZeneca PLC: Overall Financials, 2015-2017
Figure 8.11: AstraZeneca PLC: Net Revenue (by Business Segment), 2015-2017
Figure 8.12: AstraZeneca PLC: Revenue: Net Revenue (by Regions), 2015-2017
Figure 8.13: AstraZeneca PLC: R&D Expenditure, 2015-2017
Figure 8.14: AstraZeneca PLC: SWOT Analysis
Figure 8.15: Bristol-Myers Squibb: Product Portfolio
Figure 8.16: Bristol-Myers Squibb: Overall Financials
Figure 8.17: Bristol-Myers Squibb: Net Revenue (by Regions), 2015-2017
Figure 8.18: Bristol-Myers Squibb: R&D Expenditure, 2015-2017
Figure 8.19: Bristol-Myers Squibb: SWOT Analysis
Figure 8.20: Celgene Corporation: Overall Financials
Figure 8.21: Celgene Corporation: Net Revenue (by Region), 2015-2017
Figure 8.22: Celgene Corporation: R&D Expenditure, 2015-2017
Figure 8.23: Celgene Corporation: SWOT Analysis
Figure 8.24: DNAtrix Therapeutics: SWOT Analysis
Figure 8.25: Eli Lilly and Company: Product Portfolio
Figure 8.26: Eli Lilly and Company: Overall Financials, 2015-2017
Figure 8.27: Eli Lilly and Company: Net Revenue (by Business Segments), 2015-2017
Figure 8.28: Eli Lilly and Company: Net Revenue (by Regions), 2015-2017
Figure 8.29: Eli Lilly and Company: Research and Development Expenditure, 2015-2017
Figure 8.30: Eli Lilly and Company: SWOT Analysis
Figure 8.31: Gilead Sciences, Inc.: Overall Financials
Figure 8.32: Gilead Sciences, Inc.: Net Revenue (by Region), 2015-2017
Figure 8.33: Gilead Sciences, Inc.: Research and Development Expenditure, 2015-2017
Figure 8.34: Gilead Sciences, Inc.: SWOT Analysis
Figure 8.35: Fate Therapeutics: Overall Financials
Figure 8.36: Fate Therapeutics: Research and Development Expenditure, 2015-2017
Figure 8.37: Fate Therapeutics: SWOT Analysis
Figure 8.38: F. Hoffmann La Roche AG: Product Portfolio
Figure 8.39: F. Hoffmann La Roche: Overall Financials
Figure 8.40: F. Hoffmann La Roche: Net Revenue (by Business Segment), 2015-2017
Figure 8.41: F. Hoffmann La Roche: Net Revenue (by Geographic Regions), 2015-2017
Figure 8.42: F. Hoffmann La Roche: Research and Development Expense, 2015-2017
Figure 8.43: F. Hoffmann La Roche: SWOT Analysis
Figure 8.44: JOHNSON & JOHNSON: Overall Financials, 2015-2017
Figure 8.45: JOHNSON & JOHNSON (by Business Segment), 2015-2017
Figure 8.46: JOHNSON & JOHNSON (by Region), 2015-2017
Figure 8.47: JOHNSON & JOHNSON: Research and Development Expense, 2015-2017
Figure 8.48 JOHNSON & JOHNSON: SWOT ANALYSIS
Figure 8.49: Merck & Co, Inc.: Product Portfolio
Figure 8.50: Merck & Co, Inc.: Overall Financials
Figure 8.51: Merck & Co, Inc. (by Business Segment), 2015-2017
Figure 8.52: Merck & Co, Inc (by Geographic Regions), 2015-2017
Figure 8.53: Merck & Co, Inc.: Research and Development Expense, 2015-2017
Figure 8.54: Merck & Co, Inc.: SWOT Analysis
Figure 8.55: Novartis AG: Cancer Immunotherapy Product Portfolio
Figure 8.56: Novartis AG: Overall Financials (2015-2017)
Figure 8.57: Novartis AG (by Business Segment), 2015-2017
Figure 8.58 Novartis AG (by Geographic Region), 2015-2017
Figure 8.59 Novartis AG: Research and Development Expenditure, 2015-2017
Figure 8.60: Novartis AG: SWOT Analysis
Figure 8.61: Pfizer, Inc.: Cancer Immunotherapy Product Portfolio
Figure 8.62: Pfizer, Inc.: Overall Financials, 2015-2017
Figure 8.63: Pfizer, Inc.: Net Revenue (by Business Segment), 2015-2017
Figure 8.64: Pfizer, Inc.: Net Revenue (by Region), 2015-2017
Figure 8.65: Pfizer, Inc.: Research and Development Expense, 2015-2017
Figure 8.66: Pfizer, Inc.: SWOT Analysis
Figure 8.67: Precision BioSciences, Inc.: SWOT Analysis
Figure 9.1: Global Cancer Immunotherapy Market Segmentation
Figure 9.2: Research Methodology
Figure 9.3: Primary Research Sources
Figure 9.4: Secondary Research Sources
Figure 9.5: Key Data Points from Primary and Secondary Sources
Figure 9.6: Data Triangulation
Figure 9.7: Top-Down Approach: Global Cancer Immunotherapy Market
Figure 9.8: Bottom-up Approach: Global Cancer Immunotherapy Market
Figure 9.9: Assumptions and Limitations
